Arbutus Biopharma

Arbutus Biopharma Corporation
Company typePublic
Nasdaq: ABUS
Russell 2000 Component
IndustryBiotechnology
Founded2007; 17 years ago (2007)
Headquarters
Vancouver, British Columbia, Canada
ProductsHBV Therapies, AB-729, AB-836
Websitehttp://arbutusbio.com/

Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.[1]

It is headquartered in Warminster, Pennsylvania.[2] The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

  1. ^ "Arbutus' hepatitis B drug shows Phase 2 promise". BioPharma Dive. Retrieved 2019-01-25.
  2. ^ George, John (August 19, 2016). "Major tenant leaving Pa. Biotechnology Center for more space in Warminster". Philadelphia Business Journal.